Journal: Scientific Reports
Article Title: Moxifloxacin releasing intraocular implant based on a cross-linked hyaluronic acid membrane
doi: 10.1038/s41598-021-03605-0
Figure Lengend Snippet: Evaluation of MXF-HA efficacy using a rabbit model. ( A ) MXF-HA is inserted into the anterior chamber through a corneal incision while folded by forceps (yellow arrow). The unfolded circular MXF-HA is visible inside the anterior chamber immediately after implantation (white arrows indicate the margin of MXF-HA). ( B ) The implanted MXF-HA was visible on day 1 after surgery (white arrows). However, no visible MXF-HA structures were detected on days 7 and 14 after the surgery. Control is the contralateral eye without MXF-HA insertion. ( C ) MXF concentration was measured using aqueous humor collection. MXF concentrations in aqueous humor were maintained above 8 μg/mL for 5 days. ( D ) The intraocular pressure of MXF-HA-implanted eyes was not significantly different from that of the contralateral control eyes and was maintained within the normal range. ( E ) Eyeballs were harvested and imaged using optical coherence tomography (OCT). Normal corneal structure and thickness were maintained in both MXF-HA and control eyes. Histology (hematoxylin and eosin [H&E] staining) showed normal cellularity in all corneal layers without signs of inflammation in both MXF-HA and control eyes. ( F ) Specular microscopy revealed normal density and morphology of corneal endothelial cells in both MXF-HA and control eyes. *p < 0.05, **p < 0.01, ***p < 0.001.
Article Snippet: The corneal endothelial safety of MXF-HA was analyzed using human corneal endothelial cell line (B4G12, Creative Bioarray, Shirley, NY, USA).
Techniques: Control, Concentration Assay, Tomography, Staining, Microscopy